ClinicalTrials.gg
CompletedNCT01967147Updated Mar 23, 2016Results posted

Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects

An interventional study of Propylene Glycol, 0.6% eye drops and Preservative-free 0.9% Saline solution in Dry Eye, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-23.

Sponsored by Alcon Research (part of Alcon) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing Propylene Glycol in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Propylene Glycol · Dry Eye Syndromes.

Enrollment
Largest of 12
279 · median 87
Started
2014
the only one that year
No phase
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
Alcon Research

Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, this one has the largest enrollment, is the only one that started in 2014, is one of 3 with no phase, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 12 studies testing Propylene Glycol in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About Propylene Glycol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Propylene Glycol in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the superior efficacy of Systane® Balance over Preservative-Free 0.9% Saline following 35 days of QID (4 times a day) dosing in treating dry eye subjects with lipid deficiency.

Read the detailed description

This study consisted of 4 visits conducted during 3 sequential phases: the Run-in Phase (which included a screening visit and run-in period), Treatment Phase I and Treatment Phase II. In Phase I, subjects were randomized to either Systane® Balance or Saline and dosed 4 times a day for 35 days. In Phase II (Day 35-90) subjects continued to dose with their assigned product on an as-needed basis.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry eye
  • Lipid deficiency
  • Tear film break-up time
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have all of the following in at least 1 eye at Screening:

    1. Meibomian Gland Dysfunction (MGD) grading for Expressibility ≤ 2 and Meibum Quality ≤ 2,
    2. The average of 3 measures of TFBUT ≤ 5 seconds, and
    3. Unanesthetized Schirmer I test of ≥ 3 mm.
  • Must have an Ocular Surface Disease Index (OSDI) Score ≥ 18 at Visit 1 prior to randomization (ie, after 2 weeks of run-in with Preservative-Free 0.9% Saline administered 4 times a day).
  • Must have best-corrected visual acuity of 55 letters or better in each eye as assessed using an early treatment diabetic retinopathy study (ETDRS) chart (letter read method).
  • Physician diagnosis of dry eye at least 6 months prior to Screening visit.
  • Willing and able to attend all study visits.
  • Must sign a written form.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Subjects on topical ocular treatments containing benzalkonium chloride (BAK), or other products with known toxicity to the corneal surface, within 30 days of Screening.
  • Subjects who have started, stopped, or changed a lid hygiene regimen within 30 days of Screening.
  • Use of any artificial tears/lubricants/gels/rewetting drops within 4 hours of Screening.
  • Women of are excluded from participating in this study if they met any of the following conditions:

    • Currently pregnant, or
    • Test positive for pregnancy at Screening visit, or
    • Currently breast feeding, or
    • Are not in agreement to use adequate methods to prevent pregnancy throughout the study.
  • to the use of any of the study products or allergy to any ingredient in the study products.
  • Has an active ocular allergy.
  • Any ocular abnormalities that could adversely affect the safety or efficacy outcome, including eyelid anomalies, corneal disorders, history of herpes simplex, etc.
  • Subjects taking any systemic medication known to cause dry eye unless they have been on stable therapy/dosage for at least 30 days prior to Screening and will remain on a stable dosage for the duration of the study.
  • History of any ocular or intraocular surgery (including periocular Botox injections), eyelid surgery, keratorefractive procedure, corneal transplant and its variants, or serious ocular trauma within 1 year of Screening.
  • Active ocular infection (bacterial, viral or fungal), active inflammation not associated with dry eye such as uveitis, iritis, active blepharitis, active allergic conjunctivitis, etc.
  • Subjects with punctal plug insertion or diathermy procedure initiated within 30 days of Screening.
  • Any significant illnesses that could be expected to interfere with the study parameters.
  • Subjects with active oculodermal rosacea with meibomian gland dysfunction.
  • Participation in an drug or device trial within 30 days of Screening.
  • Contact lens use within 30 days prior to Screening, or unwilling to avoid contact lens use during the course of the study.
  • Unwilling to avoid the use of additional artificial tears/lubricants/gels/rewetting drops (other than the assigned study medication) throughout the course of the study.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Systane Balance

    Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).

    Drug: Propylene Glycol, 0.6% eye drops

  • Active comparator
    Saline

    Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).

    Drug: Preservative-free 0.9% Saline solution

Interventions

  • Commercially available eye drops used during Treatment Phase

    Also known as: Systane® Balance

  • DrugPreservative-free 0.9% Saline solution

    Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase

06

What researchers measure

Primary outcomes

  1. Change From Baseline in TFBUT at Day 35

    TFBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using ophthalmic dye and a biomicroscope and measured in seconds. Subjects were dosed in the office 1 hour ±10 minutes prior to TFBUT assessment. A shorter TFBUT indicates a higher likelihood of dry eye symptoms. A positive change indicates an improvement in TFBUT. One eye (study eye) contributed to the analysis.

    Time frame: Baseline (Day 0), Day 35

Secondary outcomes

  1. Change From Baseline in TOSS Score at Day 35

    The TOSS score (a cumulative cornea and conjunctival staining score) was assessed by the investigator using ophthalmic dye and a biomicroscope. Three areas of the ocular surface were graded for dryness on a 0-5 scale (0=Absent, 5=Severe), with a resultant overall score of 0-15. A negative change indicates an improvement in dry eye-related staining. One eye (study eye) contributed to the analysis.

    Time frame: Baseline (Day 0), Day 35

  2. Change From Baseline in OSDI Score at Day 35

    The OSDI is a 12-item quality of life questionnaire designed to assess ocular surface symptoms, their severity, and their impact on the subject's ability to function. Each item was scored by the subject on a 0-4 Likert-type scale (0=None, 4=All of the Time), with a resultant overall score of 0-100 (0=no disability, 100=complete disability). A negative change number represents a perceived improvement in ocular health.

    Time frame: Baseline (Day 0), Day 35

  3. Change From Baseline in IDEEL Treatment Effectiveness Score at Day 35

    The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment effectiveness questions (Questions 2-5) using a 0-4 Likert-type scale, where 0=None of the time and 4=All of the time. The IDEEL treatment effectiveness score was calculated as the sum of the responses from Questions 2-5 divided by the number of questions (2-5) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.

    Time frame: Baseline (Day 0), Day 35

  4. Change From Baseline in IDEEL Treatment Inconvenience Score at Day 35

    The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment inconvenience questions (Questions 6, 8-10) using a 0-4 Likert-type scale, where 0=All of the time and 4=None of the time. The IDEEL treatment inconvenience score was calculated as the sum of the responses from Questions 6, 8-10 divided by the number of questions (6, 8-10) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.

    Time frame: Baseline (Day 0), Day 35

07

Results

Posted Mar 23, 2016

Participant flow

Subjects were recruited from 14 study centers located in France, 4 study centers located in Germany, 3 study centers located in Spain, 3 study centers located in the Netherlands, 4 study centers located in the UK, 4 study centers located in Italy, and 3 study centers located in Poland.

Participant flow — Overall Study
MilestoneSystane BalanceSaline
Started112102
Completed9982
Not completed1320
Withdrew: Adverse event52
Withdrew: Lack of efficacy14
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject24
Withdrew: Non-compliance with study drug03
Withdrew: Other45

Outcome measures

PrimaryChange From Baseline in TFBUT at Day 35

TFBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using ophthalmic dye and a biomicroscope and measured in seconds. Subjects were dosed in the office 1 hour ±10 minutes prior to TFBUT assessment. A shorter TFBUT indicates a higher likelihood of dry eye symptoms. A positive change indicates an improvement in TFBUT. One eye (study eye) contributed to the analysis.

Time frame:
Baseline (Day 0), Day 35
Reported as:
Mean · seconds
Change From Baseline in TFBUT at Day 35
secondsSystane BalanceSaline
Change From Baseline in TFBUT at Day 351.5 ± 0.20.5 ± 0.2
SecondaryChange From Baseline in TOSS Score at Day 35

The TOSS score (a cumulative cornea and conjunctival staining score) was assessed by the investigator using ophthalmic dye and a biomicroscope. Three areas of the ocular surface were graded for dryness on a 0-5 scale (0=Absent, 5=Severe), with a resultant overall score of 0-15. A negative change indicates an improvement in dry eye-related staining. One eye (study eye) contributed to the analysis.

Time frame:
Baseline (Day 0), Day 35
Reported as:
Mean · units on a scale
Change From Baseline in TOSS Score at Day 35
units on a scaleSystane BalanceSaline
Change From Baseline in TOSS Score at Day 35-0.81 ± 0.14-0.64 ± 0.15
SecondaryChange From Baseline in OSDI Score at Day 35

The OSDI is a 12-item quality of life questionnaire designed to assess ocular surface symptoms, their severity, and their impact on the subject's ability to function. Each item was scored by the subject on a 0-4 Likert-type scale (0=None, 4=All of the Time), with a resultant overall score of 0-100 (0=no disability, 100=complete disability). A negative change number represents a perceived improvement in ocular health.

Time frame:
Baseline (Day 0), Day 35
Reported as:
Mean · units on a scale
Change From Baseline in OSDI Score at Day 35
units on a scaleSystane BalanceSaline
Change From Baseline in OSDI Score at Day 35-13.7 ± 1.44-8.38 ± 1.56
SecondaryChange From Baseline in IDEEL Treatment Effectiveness Score at Day 35

The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment effectiveness questions (Questions 2-5) using a 0-4 Likert-type scale, where 0=None of the time and 4=All of the time. The IDEEL treatment effectiveness score was calculated as the sum of the responses from Questions 2-5 divided by the number of questions (2-5) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.

Time frame:
Baseline (Day 0), Day 35
Reported as:
Mean · units on a scale
Change From Baseline in IDEEL Treatment Effectiveness Score at Day 35
units on a scaleSystane BalanceSaline
Change From Baseline in IDEEL Treatment Effectiveness Score at Day 3521.51 ± 2.435.50 ± 2.65
SecondaryChange From Baseline in IDEEL Treatment Inconvenience Score at Day 35

The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment inconvenience questions (Questions 6, 8-10) using a 0-4 Likert-type scale, where 0=All of the time and 4=None of the time. The IDEEL treatment inconvenience score was calculated as the sum of the responses from Questions 6, 8-10 divided by the number of questions (6, 8-10) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.

Time frame:
Baseline (Day 0), Day 35
Reported as:
Mean · units on a scale
Change From Baseline in IDEEL Treatment Inconvenience Score at Day 35
units on a scaleSystane BalanceSaline
Change From Baseline in IDEEL Treatment Inconvenience Score at Day 351.30 ± 1.560.77 ± 1.70

Adverse events

Collected over Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 90 days). AEs were reported as pretreatment and treatment-emergent. Ocular adverse events are presented for both study eye and non-study eye.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pretreatment—0/279 (0%)0/279 (0%)
Systane Balance—2/110 (1.8%)6/110 (5.5%)
Saline—2/100 (2%)1/100 (1%)
Most frequent serious events
Most frequent serious events
EventPretreatmentSystane BalanceSaline
Femur fractureInjury, poisoning and procedural complications0/2790/1101/100
Renal cyst excisionSurgical and medical procedures0/2790/1101/100
Arterial haemorrhageVascular disorders0/2790/1101/100
Multiple fracturesInjury, poisoning and procedural complications0/2791/1100/100
Laryngeal operationSurgical and medical procedures0/2791/1100/100
Most frequent other events
Most frequent other events
EventPretreatmentSystane BalanceSaline
Eye irritationEye disorders0/2796/1101/100

Baseline characteristics

This analysis population includes all randomized subjects.

Age, Continuous
Age, Continuous(years)Systane BalanceSalineTotal
Mean59.5 ± 15.558.4 ± 14.059.0 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Systane BalanceSalineTotal
Female9172163
Male213051
Tear Film Break-up Time (TFBUT)
Tear Film Break-up Time (TFBUT)(seconds)Systane BalanceSalineTotal
Mean3.73 ± 1.373.71 ± 1.593.72 ± 1.48
Total Ocular Surface Staining (TOSS) Score
Total Ocular Surface Staining (TOSS) Score(units on a scale)Systane BalanceSalineTotal
Mean3.45 ± 2.143.35 ± 2.383.40 ± 2.25
Ocular surface disease index (OSDI)
Ocular surface disease index (OSDI)(units on a scale)Systane BalanceSalineTotal
Mean40.24 ± 17.4838.27 ± 17.3939.30 ± 17.42
Impact of Dry Eye on Everyday Life (IDEEL) Treatment Effectiveness Score
Impact of Dry Eye on Everyday Life (IDEEL) Treatment Effectiveness Score(units on a scale)Systane BalanceSalineTotal
Mean44.63 ± 27.3246.15 ± 27.8645.35 ± 27.52
IDEEL Treatment Inconvenience
IDEEL Treatment Inconvenience(units on a scale)Systane BalanceSalineTotal
Mean76.61 ± 22.0874.48 ± 24.8575.60 ± 23.40
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Oct 22, 2013
Start
Feb 2014
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Mar 23, 2016
Last update
Mar 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01967147
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Oct 22, 2013
Start date
Feb 2014
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Mar 23, 2016
Last update
Mar 23, 2016

Study contacts

Senior Clinical Manager, GCRA
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propylene Glycol

Start the discussion